Juniper Pharmaceuticals

Juniper Pharmaceuticals is developing therapeutics that address unmet medical needs in women’s health. The Company's current pipeline leverages the 505(b)(2) regulatory pathway with new formulations of existing pharmaceuticals. Juniper's current intravaginal ring product candidates are JNP-0101, an oxybutynin IVR for the treatment of overactive bladder in women; JNP-0201, a combination estrogen + progesterone IVR for menopausal symptoms; and, JNP-0301, a progesterone IVR for the prevention of preterm birth in women with a short cervical length at mid-pregnancy.

Company Growth (employees)
Type
Public
HQ
Boston, US
Founded
1986
Size (employees)
139 (est)
Juniper Pharmaceuticals was founded in 1986 and is headquartered in Boston, US

Juniper Pharmaceuticals Office Locations

Juniper Pharmaceuticals has an office in Boston
Boston, US (HQ)
33 Arch St

Juniper Pharmaceuticals Financials and Metrics

Juniper Pharmaceuticals Financials

Juniper Pharmaceuticals's revenue was reported to be $11.2 b in Q1, 2017
USD

Revenue (Q1, 2017)

11.2 b

Gross profit (Q1, 2017)

4.7 b

Gross profit margin (Q1, 2017), %

42%

Net income (Q1, 2017)

(1.4 b)

EBIT (Q1, 2017)

(1.5 b)

Market capitalization (19-Oct-2017)

50.4 m

Cash (31-Mar-2017)

21.8 m
Juniper Pharmaceuticals's current market capitalization is $50.4 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

29.2 m32.5 m37.6 m54.6 m

Revenue growth, %

11%16%45%

Cost of goods sold

13.3 m17.7 m21.4 m24.3 m

Gross profit

16 m14.8 m16.1 m30.3 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

6.9 m11.5 m8.3 m10.2 b11.5 b12.1 m11.9 m11.6 m11.2 b

Cost of goods sold

3.9 m5.1 m4.9 m5.6 b6.4 b6.4 m6.5 m5.7 m6.6 b

Gross profit

3 m6.4 m3.4 m4.6 b5 b5.8 m5.4 m5.9 m4.7 b

Gross profit Margin, %

44%56%41%45%44%48%46%51%42%
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

20.7 m16.8 m13.9 m21 m

Accounts Receivable

7.2 m5.3 m181 k

Inventories

2.6 m3.2 m3.6 m5.6 m

Current Assets

32.2 m26.4 m26.7 m34.7 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

11.8 m16.4 m16.3 m16.1 m17.4 m13.5 m13 m15 m21.8 m

Accounts Receivable

7.2 m5.3 m4.8 m6.5 m7.9 m8 m6.2 m5.3 m4.5 m

Inventories

3.6 m2.9 m3.3 m3.8 m3.1 m3.2 m3.9 m4.8 m5.7 m

Current Assets

24 m25.8 m26.1 m28.6 m30.7 m27.5 m26.4 m26.4 m33.5 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

6.7 m3.4 m(2.1 m)6 m

Depreciation and Amortization

919.1 k2 m1.9 m1.9 m

Accounts Receivable

(2.3 m)1.7 m(2.5 m)192 k

Inventories

46.5 k(619 k)(424 k)(2 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

622 k4.3 m(692 k)(1 m)(65 k)362 k(1.7 m)248 k(1.4 b)

Depreciation and Amortization

949 k1.5 m523 k1 m1.5 m

Accounts Receivable

149 k1.9 m353 k(1.1 m)(2.7 m)8 m6.2 m5.3 m4.5 m

Inventories

(966 k)(273 k)(130 k)(579 k)94 k3.2 m3.9 m4.8 m5.7 m
USDY, 2017

Revenue/Employee

80.9 m

Financial Leverage

1.5 x
Show all financial metrics

Juniper Pharmaceuticals Operating Metrics

FY, 2016

Patents Issued

4
Show all operating metrics

Juniper Pharmaceuticals Market Value History

Traffic Overview of Juniper Pharmaceuticals

Juniper Pharmaceuticals Company Life and Culture

You may also be interested in